Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Prostate Cancer treatment details. Chemotherapy. Cancer Center, Warsaw, Poland

Survival: 29.0 months
Toxicity Grade: 4
Treatments: Chemotherapy
Country: Poland
City/State/Province: Warsaw
Hospital: Cancer Center
Journal: Link
Date: 3/2014

This phase 2 study involved castration-resistant prostate cancer patients who were divided into two separate treatment groups. Group A consisted of 98 patients with a median age of 69.07 years. Group B had 51 patients with a median age of 69.97 years.

Patients in group A were treated with the chemotherapy agent docetaxel and the biologic therapy called LY2181308, an antisense surviving oligonucleotide that inhibits the surviving protein to help cause cell death.

Patients in group B were treated with docetaxel alone.

There were three treatment-related deaths in group A due to unspecified causes. Grade 4 neutropenia and leukopenia were also reported.

The most severe toxicities were grade 4 neutropenia and leukopenia. Grade 3 fatigue was also reported.

The median overall survival rates for group A and B were 27.04 and 29.04 months, respectively.

This study was supported by Eli Lilly.

Correspondence: Dr. Paweł Wiechno; email:

E-mail to a Friend Email Physician More Information